Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Secukinumab improves the quality‐of‐life of family members and partners of people with psoriasis: Family Dermatology Life Quality Index (FDLQI) results from a randomised open‐label study (SIGNATURE)

Finlay, A. Y. ORCID: https://orcid.org/0000-0003-2143-1646, Barker, J. N., Burden, A. D., Griffiths, C. E. M., Kirby, B., Goodman, M. L., Neill, C. and Warren, R. B. 2022. Secukinumab improves the quality‐of‐life of family members and partners of people with psoriasis: Family Dermatology Life Quality Index (FDLQI) results from a randomised open‐label study (SIGNATURE). JEADV Clinical Practice 1 (3) , pp. 207-218. 10.1002/jvc2.42

[thumbnail of jvc2.42.pdf] PDF - Published Version
Available under License Creative Commons Attribution.

Download (759kB)

Abstract

Abstract: Background: The Family Dermatology Life Quality Index (FDLQI) was developed to meet a need for a dermatology‐specific family member/partner quality‐of‐life (QoL) measure. This paper focuses on the analysis and interpretation of FDLQI data (used as an exploratory outcome) collected in the SIGNATURE study. Objectives: To measure the impact of secukinumab therapy for moderate to severe plaque psoriasis on the QoL of family members/partners of patients. Methods: Randomised, open‐label, non‐comparator study in 53 dermatology centres in the UK and Republic of Ireland. Patients received secukinumab 300 or 150 mg subcutaneously weekly for 4 weeks, then 4‐weekly. FDLQI Results: Family members of PASI 75 responders and non‐responders showed improved FDLQI compared to baseline, greater for responders. There was a high level of correlation between FDLQI and Dermatology Life Quality Index (DLQI) scores and positive correlations across all mapped FDLQI and DLQI questions, and a close association between the scales at all timepoints. The estimated FDLQI scores were consistently 56% of those obtained for DLQI. There was an improvement for all FDLQI questions at Week 16 with a mean total score change of 8.2. Most family member subjects had an improved score for all FDLQI questions (75%–91%, Week 12, and 77%–91%, Week 16). Family subjects with a corresponding patient visit DLQI score >10 improved for all FDLQI questions at Week 16 (mean total score change of 5.2). Conclusions: Successful therapy for severe psoriasis greatly improved QoL of family members/partners. The FDLQI questionnaire responds well and appropriately to major changes in the disease severity of those affected by plaque psoriasis.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Additional Information: License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by/4.0/
Publisher: Wiley Open Access
ISSN: 2768-6566
Date of First Compliant Deposit: 30 June 2022
Date of Acceptance: 23 May 2022
Last Modified: 03 May 2023 03:08
URI: https://orca.cardiff.ac.uk/id/eprint/150917

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics